Patents by Inventor Anders Hasager Boss

Anders Hasager Boss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of ultrarapid acting insulin
    Patent number: 9597374
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: March 21, 2017
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • POTENTIATION OF GLUCOSE ELIMINATION
    Publication number: 20150174210
    Abstract: Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia. In particular, methods of potentiating the activity of endogenous insulin in type 2 diabetics and exogenous long-acting insulin in diabetics requiring basal insulin replacement are provided.
    Type: Application
    Filed: March 5, 2015
    Publication date: June 25, 2015
    Inventors: Anders Hasager Boss, Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
  • Potentiation of glucose elimination
    Patent number: 9006175
    Abstract: Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia. In particular, methods of potentiating the activity of endogenous insulin in type 2 diabetics and exogenous long-acting insulin in diabetics requiring basal insulin replacement are provided.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: April 14, 2015
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Solomon S. Steiner, Rodney J. Woods, Joseph W. Sulner
  • Use of Ultrarapid Acting Insulin
    Publication number: 20140100158
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: December 10, 2013
    Publication date: April 10, 2014
    Applicant: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Method of treating diabetes type 2 by administering ultrarapid acting insulin
    Patent number: 8623817
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: January 17, 2012
    Date of Patent: January 7, 2014
    Assignee: Mannkind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Method of controlling glycemia by ultrarapid acting insulin without adjusting an insulin dose for meal content
    Patent number: 8258095
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: September 4, 2012
    Assignee: MannKind Corporation
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of Ultrarapid Acting Insulin
    Publication number: 20120122775
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: January 25, 2012
    Publication date: May 17, 2012
    Applicant: MANNKIND CORPORATION
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • Use of Ultrarapid Acting Insulin
    Publication number: 20120115777
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: January 17, 2012
    Publication date: May 10, 2012
    Applicant: MANNKIND CORPORATION
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Method of treating diabetes type 2 by metformin and an ultrarapid acting insulin
    Patent number: 8119593
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Grant
    Filed: August 11, 2009
    Date of Patent: February 21, 2012
    Assignee: MannKind Corporation
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci
  • Superior Control of Blood Glucose in Diabetes Treatment
    Publication number: 20110183901
    Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
    Type: Application
    Filed: March 31, 2011
    Publication date: July 28, 2011
    Applicant: MANNKIND CORPORATION
    Inventors: Wayman Wendell Cheatham, Anders Hasager Boss
  • Superior control of blood glucose in diabetes treatment
    Patent number: 7943572
    Abstract: Methods related to the treatment of diabetes and improving the control of blood glucose levels are provided. In particular, methods are provided for effectively reducing postprandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration. Additionally, methods for effectively reducing post-prandial glucose excursions while reducing the incidence of clinically significant late postprandial hypoglycemia by administered an insulin composition in a form suitable for pulmonary administration along with a long-acting basal insulin.
    Type: Grant
    Filed: March 31, 2006
    Date of Patent: May 17, 2011
    Assignee: MannKind Corporation
    Inventors: Wayman Wendell Cheatham, Anders Hasager Boss
  • USE OF ULTRARAPID ACTING INSULIN
    Publication number: 20100035795
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 11, 2010
    Inventors: Anders Hasager Boss, Richard Petrucci, Campbell Howard, Alfred Mann
  • USE OF ULTRARAPID ACTING INSULIN
    Publication number: 20100035794
    Abstract: Disclosed herein are improved methods of treating hyperglycemia with a combination of an ultrarapid acting insulin and insulin glargine comprising prandial administration of the ultrarapid insulin, and administration of a first dose of insulin glargine within 6 hours of waking for a day.
    Type: Application
    Filed: August 11, 2009
    Publication date: February 11, 2010
    Inventors: Peter Richardson, Robert A. Baughman, Elizabeth Potocka, Anders Hasager Boss, Richard Petrucci